Floatz Rating
B58/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04847063CT.gov Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies | — | Recruiting | — | — | — |
NCT01639911CT.gov Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | — | Completed | — | — | — |
NCT01375699CT.gov Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Digestive System Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | National Cancer Institute (NCI) | P2 | B · 58 |
| Dexasone | Cedars-Sinai Medical Center | P4 | BB |
| (±)-2-(O-Chlorophenyl)-2-(Methylamino)Cyclohexanone | Brian Anderson, MD | P4 | BB |
| Irinotecan | Amgen | P2 | BB |
| Fluorouracilum | Alliance for Clinical Trials in Oncology | P2 | BB |
| Mlf 541 | B. Braun Melsungen AG | P3 | BB |
| Marcaine | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | P4 | BB |
| Epinephrine | Cedars-Sinai Medical Center | P4 | BB |
| Durvalumab | M.D. Anderson Cancer Center | P2 | B |
+42 more in the Digestive System Cancer cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Digestive System Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-digestive-system-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →